Dtsch Med Wochenschr 2016; 141(08): 544-549
DOI: 10.1055/s-0041-111436
Dossier
Kollagenosen
© Georg Thieme Verlag KG Stuttgart · New York

Sjögren-Syndrom

Sjögren’s syndrome
Diana Ernst
1   Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover
,
Torsten Witte
1   Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover
› Author Affiliations
Further Information

Publication History

Publication Date:
14 April 2016 (online)

Zusammenfassung

Das Sjögren-Syndrom ist eine häufige autoimmune Erkrankung, die mit einer lymphozytären Infiltration der Tränen- und Speicheldrüsen und so mit einer Sicca-Symptomatik einhergeht. Die Abklärung der objektiven Tränen- und Speichelproduktion und extraglandulärer Manifestationen, Antikörper-Bestimmung gegen SS-A und SS-B sowie ggf. eine Speicheldrüsenbiopsie gehören zur Diagnostik. Die Mund- und Augentrockenheit wird symptomatisch behandelt, bei extraglandulären Manifestationen ähnelt die Therapie der des systemischen Lupus erythematodes.

Abstract

Sjögren’s syndrome is a frequent autoimmune disease and is associated with a lymphocytic infiltration of the lachrymal and salivary glands and with sicca symptoms. Its diagnostic procedures consist of the quantification of tear and saliva production, identification of extraglandular manifestations, measurement of antibodies against SS-A and SS-B and of salivary gland biopsies. Dry eyes and dry mouth are treated only symptomatically, whereas extraglandular manifestations are treated similar to systemic lupus erythematosus.

 
  • Literatur

  • 1 Thomas E, Hay EM, Hajeer A et al. Sjögren’s syndrome: a community-based study of prevalence and impact. Br J Rheumatol. 1998; 37: 1069-1076
  • 2 Trontzas PI, Andrianakos AA. Sjögren’s syndrome: a population-based study of prevalence in Greece. The ESORDIG study. Ann Rheum Dis 2005; 64: 1240-1241
  • 3 Qin B, Wang J, Yang Z et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 1983-1989
  • 4 Pillemer SR, Matteson EL, Jacobsson LT et al. Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001; 76: 593-599
  • 5 Witte T, Matthias T, Bierwirth J et al. Antibodies against alpha-fodrin are associated with sicca syndrome in the general population. Ann N Y Acad Sci 2007; 1108: 414-417
  • 6 Foster H, Stephenson A, Walker D et al. Linkage studies of HLA and primary Sjögren’s syndrome in multicase families. Arthritis Rheum 1993; 36: 473-484
  • 7 Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA 2001; 286: 2114-2119
  • 8 Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjögren’s syndrome. Arthritis Rheum 2004; 50: 2897-2902
  • 9 Croia C, Astorri E, Murray-Brown W et al. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren’s syndrome. Arthritis Rheum 2014; 66: 2545-2547
  • 10 Adamson 3rd TC, Fox RI, Frisman DM et al. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren’s syndrome using monoclonal antibodies. J Immunol 1983; 130: 203-208
  • 11 Robinson CP, Brayer J, Yamachika S et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren’s syndrome. Proc Natl Acad Sci U S A 1998; 95: 7538-7543
  • 12 Schein OD, Hochberg MC, Muñoz B et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 1999; 159: 1359-1363
  • 13 Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren’s syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren’s syndrome. Ann Rheum Dis 1994; 53: 637-647
  • 14 Afonso AA, Monroy D, Stern ME et al. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology 1999; 106: 803-810
  • 15 van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol 1969; 82: 10-14
  • 16 Whitcher JP, Shiboski CH, Shiboski SC et al. Sjögren’s International Collaborative Clinical Alliance Research Groups l. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren’s Syndrome International Registry. Am J Ophthalmol 2010; 149: 405-415
  • 17 Shiboski SC, Shiboski CH, Criswell L et al. Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res 2012; 64: 475-487
  • 18 Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum 1985; 28: 1128-1132
  • 19 Vitali C, Bombardieri S, Jonsson R et al; European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558
  • 20 Hermann GA, Vivino FB, Goin JE. Scintigraphic features of chronic sialadenitis and Sjögren’s syndrome: a comparison. Nucl Med Commun 1999; 20: 1123-1132
  • 21 Tonami H, Ogawa Y, Matoba M et al. MR sialography in patients with Sjögren syndrome. Am J Neuroradiol 1998; 19: 1199-1203
  • 22 Ramos-Casals M, Solans R, Rosas J et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 2008; 87: 210-219
  • 23 Witte T, Matthias T, Oppermann M et al. Prevalence of antibodies against alpha-fodrin in Sjögren’s syndrome: comparison of 2 sets of classification criteria. J Rheumatol 2003; 30: 2157-2159
  • 24 Brennan MT, Sankar V, Leakan RA et al. Risk factors for positive minor salivary gland biopsy findings in Sjögren’s syndrome and dry mouth patients. Arthritis Rheum 2002; 47: 189-195
  • 25 Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993; 36: 340-347
  • 26 Wernicke D, Hess H, Gromnica-Ihle E et al. Ultrasonography of salivary glands -- a highly specific imaging procedure for diagnosis of Sjögren’s syndrome. J Rheumatol 2008; 35: 285-293
  • 27 Niemelä RK, Takalo R, Pääkkö E et al. Ultrasonography of salivary glands in primary Sjogren’s syndrome. A comparison with magnetic resonance imaging and magnetic resonance sialography of parotid glands. Rheumatology (Oxford). 2004; 43: 875-879
  • 28 Vivino FB, Al-Hashimi I, Khan Z et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92–01 Study Group. Arch Intern Med 1999; 159: 174-181
  • 29 Sankar V, Brennan MT, Kok MR et al. Etanercept in Sjögren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004; 50: 2240-2245
  • 30 Rihl M, Ulbricht K, Schmidt RE et al. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren’s syndrome. Rheumatology 2009; 48: 796-799
  • 31 Meijer JM, Meiners PM, Vissink A et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960-968
  • 32 Gottenberg JE, Ravaud P, Puéchal X et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312: 249-258
  • 33 Gottenberg JE, Cinquetti G, Larroche C et al. Club Rhumatismes et Inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013; 72: 1026-1031
  • 34 Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337-2344